ArticlePituitary2014
Increased thyroid cancer risk in acromegaly.
Article in Pituitary, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Article
- Article
- Cancer Risk in Patients with Acromegaly: Insights from a Single Center in Ankara.Journal of clinical medicine · 2026Article
- Anemia in acromegaly: Prevalence, etiologies, and predictors from a large tertiary center cohort.Pituitary · 2025Article
- Growth Hormone Signaling in Bladder Cancer: Transcriptomic Profiling of Patient Samples and In Vitro Evidence of Therapy Resistance via ABC Transporters and EMT Activation.International journal of molecular sciences · 2025Article
- Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2025Article
- The Experience of a Single Tertiary Center Regarding Benign and Malignant Tumors in Acromegalic Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- The evaluation of breast findings detected through different visualisation techniques in acromegaly patients — a retrospective studyTurkish journal of medical sciences · 2021Article
- Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients.Journal of clinical medicine · 2021Review
- Clinical presentation and management of acromegaly in elderly patients.Hormones (Athens, Greece) · 2021Article
- A rare case of Cushing's disease concurrent with papillary thyroid carcinoma.Caspian journal of internal medicine · 2021Article
- Acromegaly and thyroid cancer: analysis of evolution in a series of patients.Clinical diabetes and endocrinology · 2020Article
- Article
- Article
- Acromegaly and papillary thyroid carcinoma: A case series.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.International journal of molecular sciences · 2018Review
- Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.Therapeutic advances in cardiovascular disease · 2018Review
- Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans.Endocrine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly increases cancer risk. We aimed to determine the prevalence and the predictors of tumors in acromegalic patients treated at our department. We retrospectively evaluated 160 acromegalic patients [79 female (mean age 52.0 ± 10.4 years) and 81 male (mean age 49.1 ± 12.4 years)] between 1990 and 2012, with a mean follow up period of 7.1 ± 5.7 years. The patients were screened with colonoscopy, mammography, thyroid and prostate ultrasonography. Malignancy was found in 34 (21.3%) patients. No significant difference was observed in the distribution of malignancy among sexes (20.3% in F vs. 22.2% in M). Thyroid cancer was the most frequent (n = 17, 10.6%) followed by the breast cancer (n = 4, 2.5%) and colorectal cancer (n = 3, 1.8%). Renal cell cancer in two patients, bladder cancer in two patients, periampullary tumor, rectal carcinoid tumor, malignant melanoma, prostate cancer, lung cancer, parotid mucoepidermoid carcinoma and malignant mesenchymal tumor in brain in one patient were detected. One patient had both thyroid and renal cell cancer. Age of patients at diagnosis of acromegaly was significantly higher in patients with cancer (45.8 ± 9.9 vs. 40.9 ± 11.3 years, p < 0.05). No significant difference was found in duration of the disease, initial GH levels and IGF-1% upper limit of normal values, the prevalence of diabetes, hypertension, coronary heart disease, hyperlipidemia and treatment modalities between the patients with/without cancer. In logistic regression analysis, older age at diagnosis was associated with malignancy risk. The risk of cancer in acromegaly especially the thyroid cancer risk seems to be more increased than known in the literature. Therefore, acromegaly patients should be screened routinely for cancer, especially for thyroid cancer due to it being up to four times higher prevalence than breast and colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.